A study published in the recent issue of the journal Cancer Immunology Research suggests that cannabidiol (CBD) may enhance the effectiveness of atezolizumab, a drug commonly used in treating triple-negative breast cancer (TNBC).
The study, which was published online ahead of print by the National Library of Medicine, highlights the potential for CBD to be used as an immune modulator, offering a new avenue for improving cancer treatments.
Triple-negative breast cancer is an aggressive form of cancer that often relies on cytotoxic therapies. Current treatments include the combination of atezolizumab, an immune checkpoint inhibitor (ICI), with chemotherapy. However, the effectiveness of this combination is limited for patients with low reactivity to atezolizumab, prompting researchers to explore alternative treatments that could enhance its efficacy.
Continue reading